| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.92% | 63.80% | 72.91% | 59.37% | 53.36% | 67.99% | 71.25% | 77.22% | 7.24% | 95.21% | 100.00% | — |
| Operating Margin | -111.00% | -191.38% | -168.43% | -268.76% | -274.08% | -206.74% | -302.54% | -446.38% | -53.95% | -398.73% | -5855.27% | — |
| EBITDA Margin | -110.36% | -189.58% | -165.79% | -264.65% | -270.26% | -201.74% | -297.30% | -441.20% | -53.33% | -393.00% | -5852.26% | — |
| Net Margin | 10.77% | -79.75% | -71.75% | -114.30% | -94.06% | -102.03% | -109.09% | -313.02% | -35.65% | -334.31% | -5611.59% | — |
| Current Ratio | 2.49 | 1.27 | 1.38 | 1.80 | 3.43 | 5.45 | 3.43 | 2.00 | 2.72 | 1.94 | 9.43 | 17.28 |
| Quick Ratio | 2.30 | 1.06 | 1.26 | 1.69 | 3.33 | 5.42 | 3.41 | 1.99 | 2.71 | 1.93 | 9.43 | 17.28 |
| Debt / Equity | 0.84 | -35.26 | 38.35 | 1.83 | 0.19 | 0.26 | 1.24 | 4.28 | 0.56 | 0.36 | 0.28 | 0.20 |
| ROE | 10.96% | 2797.87% | -3820.86% | -173.06% | -28.65% | -23.62% | -55.09% | -426.21% | -55.50% | -66.41% | -57.47% | -28.91% |
| ROA | 3.67% | -31.89% | -36.20% | -29.42% | -16.32% | -14.15% | -17.65% | -59.68% | -27.19% | -32.27% | -40.83% | -22.82% |
| Asset Turnover | 0.34 | 0.40 | 0.50 | 0.26 | 0.17 | 0.14 | 0.16 | 0.19 | 0.76 | 0.10 | 0.01 | 0.00 |
| Book Value / Share | 2.23 | -0.08 | 0.20 | 0.56 | 2.76 | 2.74 | 1.33 | 0.45 | 2.89 | 2.08 | 2.15 | 1.94 |
Fortress Biotech Inc. operates as a biopharmaceutical company involved in the development and commercialization of novel pharmaceutical and biotechnology products. Its primary function is to nurture and advance a diverse portfolio of potential new treatments for rare diseases, cancer, and other serious health conditions. A distinctive feature of Fortress Biotech is its innovative partnership model; it acquires, develops, and commercializes these therapies through multiple subsidiary companies and licensing agreements. This structure allows for specialized focus and flexibility in progressing early-stage drug candidates. Fortress Biotech significantly impacts the healthcare sector, particularly in areas of unmet medical needs where it seeks to bring breakthrough therapies to market. By creating a platform for research and development across its subsidiaries, the company plays a crucial role in fostering advancements in medical treatments and addressing critical gaps within pharmaceutical innovation and patient care.